Objectives: The main aim of this study was to compare the optimal dose of GnRH agonist for triggering ovulation in PCOS cases to obtain the best outcome. Therefore, we studied the difference between 0.1 ml and 0.2 ml Decapeptyl and the pregnancy rate in each group as a primary outcome.
Study Design: A retrospective non-randomized study.
Materials and Methods: The study was approved by the medical ethical committee of the Faculty of Medicine, Alexandria University. It was conducted on 227 patients who were diagnosed with PCOS and indicated for ICSI. All cases were stimulated by GnRH antagonist protocol and triggered by GnRH agonist triptorelin for final ovarian maturation. They were allocated into two groups. The first group (n=163) was triggered by triptorelin 0.1mg (Decapeptyl 0.1 mg, Ferring®), and the second group (n=64) was triggered by triptorelin 0.2mg (Decapeptyl 0.2 mg, Ferring®). The two groups underwent ICSI and frozen all embryos followed by thawed embryo transfer in an artificial endometrial priming cycle from April 2018 to December 2020.
Results: The difference in the pregnancy rate of Day 3 thawed embryos was not statistically significant (77.8% and 62.8% respectively, p=0.127), while the rate in Day 5 thawed embryos was higher in group A (82.2% and 61.9% respectively, p=0.040).
Conclusion: The chance of pregnancy in the first group is approximately 2.5 times more than the chance of pregnancy in the second Group regarding Day 5 embryos.